+ Watch MYGN
on My Watchlist
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.
Negative long-term earnings growth, low cash flow and book value, no dividend. Will lose market share to upstarts with less expensive tests.The likely next President, Hillary Clinton, will aggressively try to reign in health care spending at the expense of the industry.
I am a firm beliver this sector has not even begun to hit it's stride.
Short Ratio is unusual high.
It relies on BRCA testing, which will see extreme price pressure from payors
Great company in a high growth sector ( diagnostics )
biotech w/ profits!! This company has minimal debt & phenomenal ROIC and ROE. They are currently on a pullback, but it is time to jump in!
Too high, too fast.
I have some shares.
I just have a feeling. This is going to 60 a share in 3 years. Amazing product line until the patents run out and then business will become competitive. Revs increasing setting up for the perfect storm on performance
Bought rival. Beat estimates.
Sold fundamentals. Why do doctors want to know your family history? To provide preventive guidance. The diagnostic tests this company provides quantify this information in a very specific way. Even though Medicare will no longer pay for these tests it in the younger patients not the elderly that are the target market. Affordable Care Act. In time the insurance companies will embrace this concept if it proves to cut cost of healthcare. The market over reacted to the court ruling. 47% of float shorted. Huge short squeeze on any good news.
I think the huge dip is an overreaction. I order 5 of these a month in my practice, and while there are others coming up with similar tests, there will be a lag time.
Massive Diagnostics Rx Cmpany!
BRCA1/2 testing competition from other companies that will utilize next gen sequencing techniques. Supreme court ruling eliminates Myriad's monopoly
Lost BRCA1/BRCA2 patents. They are going down.
The Affordable Care Act and publicity over A Jolie's surgery due to BRACA genes will boost sales of the BRACA genetics test, of which Myriad is the only producer.
Porte and ZZ.
Great product without the downside risks of drugs. Increasing contracts with other drug companies for use of their genetic tests for the drug co's drug trials. The future of medicine is personalized based on each inidividual.
Well run company with minimal debt. All star board of directors. The future will eventually be preventative medicine, and this company is an early mover in that field.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions